SCHEMBL23996182

SCHEMBL23996182

Cc1cc(C(F)(F)F)ccc1C=N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.43
CYP1B1 Q16678 1/20 0.43
PDE2A O00408 1/20 0.42
BACE1 P56817 1/20 0.39
KDM4E B2RXH2 1/20 0.39
NPBWR1 P48145 1/20 0.38
KIF11 P52732 3/20 0.38
CES2 O00748 1/20 0.37
NFE2L2 Q16236 1/20 0.37
EPHX2 P34913 1/20 0.37
SCN4A P35499 1/20 0.37
RIPK2 O43353 1/20 0.35
KDR P35968 1/20 0.35
MAPK14 Q16539 1/20 0.35
PTPN5 P54829 1/20 0.35
RAPGEF4 Q8WZA2 1/20 0.35
MAPT P10636 1/20 0.35
CCNE2 O96020 1/20 0.35
CCNA2 P20248 1/20 0.35
CCNE1 P24864 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3033291 0.79 CYP1A1 (0.46) CYP1A1CYP1B1PDE2ABACE1KDM4E
SCHEMBL30233883 0.79 CYP1A1 (0.43) CYP1A1CYP1B1PDE2ABACE1KDM4E
SCHEMBL25026056 0.79 CYP1A1 (0.43) CYP1A1CYP1B1PDE2ABACE1KDM4E
SCHEMBL22359538 0.78 ALDH1A1 (0.46) BACE1KDM4EKIF11CES2EPHX2
SCHEMBL12656445 0.78 CYP1A1 (0.49) CYP1A1CYP1B1PDE2ABACE1KDM4E
SCHEMBL14186116 0.77 CYP3A4 (0.38) CYP1A1CYP1B1PDE2ABACE1KDM4E
SCHEMBL21237094 0.75 BACE1 (0.43) CYP1A1CYP1B1PDE2ABACE1KDM4E
SCHEMBL25872852 0.75 CYP1A1 (0.40) CYP1A1CYP1B1PDE2ABACE1KDM4E
SCHEMBL25074678 0.73 PDE2A (0.41) PDE2ACES2MAPT
SCHEMBL14546609 0.73 AMY1A (0.44) CYP1A1CYP1B1BACE1KDM4ERAPGEF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168085-B2 Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne SYNAFFIX B.V. (NL) 2021-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168085-B2 Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne AHR, CYP1B1, NAT1 CYP1A1 5/4885CYP1B1 2/4885PDE2A 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.